Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Anastasis Biotec
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Idea== <vimeo>424748467</vimeo> Cancer is a major cause of death, killing 9.6m people in 2018. We are developing a human protein-based therapeutic product, Syntana-4 (S-4), which inhibits cancer stem cells (CSC) - the growth engine of cancer. If clinical trials are successful, S-4 could provide a desperately needed treatment option for many relapsed/resistant tumours with ‘Notch’ mutations. The global cancer drug market was at ~$200bn in 2019. S-4 would initially target use for patients with relapsed prostate cancer, which caused 3.8% of global cancer deaths in 2018. Our research indicates that S-4 could help provide a solution to combat this deadly disease. Alongside this, our research suggests S-4 will have low manufacturing costs, making it affordable, enabling ‘mass market’ sales strategy. We have secured the rights and patents related to the delivery platform for CSC and other tissue, based on a cell-penetrating protein (ANTP) which can deliver drugs into the nucleus of cells. We have raised £450k in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award and are now looking to raise to progress S-4 in collaboration with the University of Chicago’s current cancer stem cell therapeutics R&D program (partnership is pending signature). Key milestones are to complete all steps to a phase II clinical trial, demonstrate clinical efficacy and then secure an exit through M&A.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)